Bitterroot Bio Announces Dosing of First Patient in MATADOR Phase 2a Study of BRB-002, an Immunomodulating Therapy Targeting CD47 in Atherosclerotic Cardiovascular Disease

-Dosing initiated in proof-of-concept MATADOR Phase 2a study- -Initial results expected by year-end 2026- Palo Alto, California, and Needham, Massachusetts – June 2, 2025 – Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced the dosing of the first patient in its proof-of-concept MATADOR Phase 2a study in Australia, […]